| Identification | Back Directory | [Name]
4H-1-Benzopyran-4-one, 2-[2-chloro-4-[(1-methyl-1H-benzimidazol-2-yl)thio]phenyl]-5,7-dihydroxy-8-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- | [CAS]
2423045-06-9 | [Synonyms]
CDK9/10/GSK3β-IN-1
4H-1-Benzopyran-4-one, 2-[2-chloro-4-[(1-methyl-1H-benzimidazol-2-yl)thio]phenyl]-5,7-dihydroxy-8-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- | [Molecular Formula]
C29H24ClN3O4S | [MOL File]
2423045-06-9.mol | [Molecular Weight]
546.04 |
| Hazard Information | Back Directory | [Uses]
CDK9/10/GSK3β-IN-1 (compound 13c) is a kinase inhibitor (Flavopiridol (HY-10005) analogue) that effectively inhibits HsGSK3β (IC50=59 nM), HsCDK9/CyclinT (IC50=64 nM), HsCDK5/p25 (IC50=1.093 μM) and HsCDK2/CyclinA (IC50=1.725 μM). CDK9/10/GSK3β-IN-1 has anti-cancer cellular activity comparable to or higher than that of Flavopiridol. CDK9/10/GSK3β-IN-1 shows high anti-proliferative activity in vitro against up to seven cancer cell lines[1]. | [References]
[1] Ibrahim N, et al. Identification of a new series of flavopiridol-like structures as kinase inhibitors with high cytotoxic potency. Eur J Med Chem. 2020 Aug 1;199:112355. DOI:10.1016/j.ejmech.2020.112355 |
|
|